What happened
Summit Therapeutics Inc. (NASDAQ: SMMT) has released fuller survival results for its experimental lung-cancer drug ivonescimab.
The HARMONi trial compared the drug plus chemotherapy with chemotherapy alone. It enrolled patients with EGFR-mutated lung cancer that had progressed after targeted treatment. The question was whether adding the drug helped patients live longer.
The company disclosed the updated hazard ratio in July. Its September 15 release adds the confidence interval and statistical details. Those matter because the estimated benefit alone does not show how uncertain it is.
Why it matters
The April 2025 primary survival analysis produced a hazard ratio of 0.79. Its confidence interval ran from 0.62 to 1.01, crossing the no-difference threshold of 1. That original survival result missed statistical significance.
The June 2026 follow-up produced a ratio of 0.76, with a confidence interval of 0.61 to 0.95. The nominal p-value was 0.0151. This later analysis supports the case, but does not turn the original failed statistical test into a successful one.
The implied relative reduction in the hazard of death rose from 21% to 24%, a three-percentage-point improvement. That does not mean patients lived 24% longer. Global median survival stayed at 16.8 months with the combination versus 14.0 months with chemotherapy.
The Western subgroup remains the important caution. Its ratio was also 0.76, but the confidence interval ranged from 0.52 to 1.10. Because that range includes no difference, the subgroup result remains statistically inconclusive.
The update extends Western follow-up to 23.2 months. Asian patient data were locked at the earlier cutoff. It is therefore important to examine which patients supplied the additional evidence, rather than treating every observation as new.
What's next
The Food and Drug Administration has a November 14, 2026 goal date for the U.S. application. Ivonescimab remains investigational in the United States and Europe.
The investment case depends on the full regulatory review, including safety and whether the findings apply to U.S. patients. An approval and its permitted uses would matter more commercially than another encouraging statistical update. The new details reduce some uncertainty, but they do not settle those questions.